ArticleBMC palliative care2025
Life after hepatorenal syndrome: unraveling quality of life, psychological distress, and treatment preferences.
Article in BMC palliative care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHepatorenal syndrome (HRS) is a life-threatening complication of advanced liver disease, associated with high short-term mortality and persistent symptom burden among survivors. While therapeutic advances have improved survival, little is known about the long-term quality of life (QoL), psychological distress, symptom management, and care preferences in this vulnerable population.
methodsIn this prospective mixed-methods study, conducted between September 2024 and March 2025 at Robert Bosch Hospital in Stuttgart, Germany, patients who survived an HRS episode between 2019 and 2024 were identified retrospectively and invited for structured surveys. Patient-reported outcomes were assessed using the Short Form-12 (SF-12), targeted symptom and psychosocial questionnaires, and preference-oriented items. Quantitative data were analyzed descriptively and comparatively; open-ended responses were evaluated using qualitative content analysis.
resultsFifteen HRS survivors (mean age 62 ± 13 years; 33% male; 73% with alcohol-related cirrhosis) participated. Mean scores on the physical component summary (PCS-12) and mental component summary (MCS-12) of the SF-12 were 42.6 ± 8.5 and 41.7 ± 7.4, respectively, indicating moderate impairment in physical and mental health. Fatigue (73%), fluid retention (53%), and dyspnea (47%) were the most frequently reported symptoms. Psychological distress was reported by 87% of patients, and 53% expressed substantial fear of rehospitalization. Treatment preferences varied: 53% favored intensive care in case of deterioration, 7% preferred a palliative approach, and 40% remained undecided.
conclusionSurvivors of HRS face considerable long-term impairments and psychosocial vulnerability. These findings underscore the need for structured multidisciplinary follow-up that integrates symptom relief, psychological support, and individualized decision-making. Given the exploratory nature and small sample size, further longitudinal studies are needed to confirm these findings and inform targeted supportive care strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.